BIGBEAR
PHARMACEUTICALS
Sotorasib covalently binds to the switch pocket of KRAS G12C mutant protein, specifically inhibits GTPase activity and blocks abnormal RAS signaling.
AuthenticGuaranteeFast DeliveryPrivacy KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasi···【Read More】
Update: 04 Mar,2026Source: Haiou HealthViews: 71
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021.I.···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 70
In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of certain adult patients with non-sm···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 70
Sotorasib is an oral targeted anticancer drug developed by Amgen, a small molecule inhibitor specifically targeting the KRAS G12C mutation.Indications···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 71
Sotorasib is a targeted drug against KRASG12C mutations, primarily used to treat malignant tumors such as non-small cell lung cancer. Common side effe···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 70
While taking sottorazib, it is generally not recommended to consume large amounts of fatty foods. However, small or occasional intake is usually harml···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 70
The usual recommended dose of sotorasib is 960 mg (8 tablets x 120 mg) once daily, taken on an empty stomach at least 1 hour before or 2 hours after e···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 70
Copyright2024@ BIGBEAR All right reserved BIGBEAR
